RT Journal Article
T1 Drug-Induced Liver Injury in Latin America: 10-year experience of the Latin American DILI (LATINDILI) Network
A1 Bessone, Fernando
A1 Hernandez, Nelia
A1 Medina-Caliz, Inmaculada
A1 García-Cortés, Miren
A1 Schinoni, María I.
A1 Mendizabal, Manuel
A1 Chiodi, Daniela
A1 Nunes, Vinicius
A1 Ridruejo, Ezequiel
A1 Pazos, Ximena
A1 Santos, Genario
A1 Fassio, Eduardo
A1 Parana, Raymundo
A1 Reggiardo, Virginia
A1 Tanno, Hugo
A1 Sanchez, Adriana
A1 Tanno, Federico
A1 Montes, Pedro
A1 Tagle, Martin
A1 Arrese, Marco
A1 Brahm, Javier
A1 Girala, Marcos
A1 Lizarzabal, M. Isabel
A1 Carrera, Enrique
A1 Zerega, Alina
A1 Bianchi, Carla
A1 Reyes, Laura
A1 Arnedillo, Daina
A1 Cordone, Antonella
A1 Gualano, Gisela
A1 Jaureguizahar, Fernanda
A1 Rifrani, Gabriel
A1 Robles‑Diaz, Mercedes
A1 Ortega-Alonso, Aida
A1 Pinazo-Bandera, José M.
A1 Stephens, Camilla
A1 Sanabria-Cabrera, Judith
A1 Bonilla-Toyos, Elvira
A1 Niu, Hao
A1 Álvarez-Álvarez, Ismael
A1 Lucena, M. Isabel
A1 Andrade, Raúl J.
K1 Hígado - Enfermedades
AB Background and aims: Latin America is a region of great interest for studying the clinical presentation of idiosyncratic drug-induced liver injury (DILI). A comprehensive analysis of patients enrolled into the LATINDILI Network over a decade is presented.Methods: Demographics, clinical presentation, histological findings and outcome of prospectively recruited DILI cases in the LATINDILI Network were analyzed. Suspected culprit drugs were classified according to the Anatomical Therapeutic Chemical classification. Causality was assessed using the Roussel Uclaf Causality Assessment Method (RUCAM) scale.Results: Overall, 468 idiosyncratic DILI cases were analyzed (62% women, mean age 49 years). Hepatocellular injury predominated (62%), jaundice was present in 60% of patients and 42% were hospitalized. 4.1% of the cases had a fatal outcome, and 24 (12%)patients developed chronic DILI. The most common drug classes were systemic antiinfectives (31%), musculoskeletal agents (12%), antineoplastic and immunomodulating agents (11%), and herbal and dietary supplements (HDS, 9%). Notably, none of the patients with DILI due to antibacterials or immunosuppressants had a fatal outcome. In fact, Hy's law showed to have drug-specific predictive value, with anti-tuberculosis drugs, nimesulide and HDS associated with the worst outcome, whereas DILI caused byamoxicillin-clavulanate, nitrofurantoin and diclofenac that fulfilled Hy's law did not have a fatal outcome.Conclusion: Features of DILI in Latin America are comparable to other prospective registries. However, the pattern of drugs responsible for DILI differs. An increasing incidence of HDS, with high mortality rate, and likewise nimesulide and nitrofurantoinwas noted. Thus, public health policies should raise awareness of the potential adverse effects of these compounds.
PB Elsevier
YR 2024
FD 2024-07
LK https://hdl.handle.net/10630/32221
UL https://hdl.handle.net/10630/32221
LA eng
NO Bessone F, Hernandez N, Medina-Caliz I, García-Cortés M, Schinoni MI, Mendizabal M, Chiodi D, Nunes V, Ridruejo E, Pazos X, Santos G, Fassio E, Parana R, Reggiardo V, Tanno H, Sanchez A, Tanno F, Montes P, Tagle M, Arrese M, Brahm J, Girala M, Lizarzabal MI, Carrera E, Zerega A, Bianchi C, Reyes L, Arnedillo D, Cordone A, Gualano G, Jaureguizahar F, Rifrani G, Robles-Díaz M, Ortega-Alonso A, Pinazo- Bandera JM, Stephens C, Sanabria-Cabrera J, Bonilla-Toyos E, Niu H, Alvarez-Alvarez I, Lucena MI, Andrade RJ. Drug-Induced Liver Injury in Latin America: 10-year experience of the Latin American DILI (LATINDILI) Network Drug-induced liver injury in Latin America. Clin Gastroenterol Hepatol. 2024. DOI: 10.1016/j.cgh.2024.06.030.
NO This work was supported by grants of Instituto de Salud Carlos III (ISCIII), cofounded by Fondo Europeo de Desarrollo Regional –FEDER, cofounded by European Union (grant number PI21/01248; PT20/00127; PT23/00137), and by the Agencia Española de Medicamentos y Productos Sanitarios. CIBERehd and Plataforma de Investigación Clinica are funded by ISCIII. JMPB holds a Rio Hortega contract (CM21/00074) and JSC a Juan Rodés contract (JR21/00066) from ISCIII and cofounded by the European Union. HN holds a postdoctoral research contract funded by Junta de Andalucía (POSTDOC_21_00780). This project has received fundingfrom the European Horizon´s research and innovation program HORIZON-HLTH-2022-STAYHLTH-02 under agreement Nº 101095679. This study is funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them. The funding sources had no involvement in the study design; in the collection, analysis, and interpretation of data; in the writing of the report or in the decision to submit the manuscript for publication.
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 19 ene 2026